Leerink Partners keeps Outperform rating on CVS Health
Leerink Partners kept its Outperform rating and $112 target for CVS Health, implying 30.0% upside from the stock’s Oct. 9 close at $86.16.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
TradingView reports that Leerink Partners maintained its Outperform rating on CVS Health shares and a $112.00 price target. The target represents a 30.0% potential gain from the Oct. 9 closing price of $86.16.
The analyst note highlights CVS Health’s diversified structure, which includes retail pharmacies, pharmacy benefit management (PBM), health insurance and primary care services. Analysts said the links between these businesses support the company’s long-term growth prospects as the healthcare market continues to evolve.
Although CVS faces pressure from the 340B program and Medicare Advantage, it has continued to generate stable cash flow and has improved margins. These factors led analysts to view the shares as undervalued. Selected reference data was provided by Benzinga.
why it matters
The assessment signals a constructive analyst view of CVS Health’s financial resilience despite pressures tied to specific healthcare programs. It is not investment advice.
instruments
sources
- Leerink Partners maintains Outperform rating on CVS Health, $112 price target — TradingView, 12 October 2026 at 12:58 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗